Abstract
BackgroundHigh tumor mutational burden (TMB) and PD-L1 expression are associated with improved clinical outcomes in patients (pts) with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). However,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have